标题
Smoldering multiple myeloma requiring treatment: time for a new definition?
作者
关键词
-
出版物
BLOOD
Volume 122, Issue 26, Pages 4172-4181
出版商
American Society of Hematology
发表日期
2013-10-22
DOI
10.1182/blood-2013-08-520890
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
- (2013) S V Rajkumar et al. LEUKEMIA
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
- (2013) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Total cost comparison in relapsed/refractory multiple myeloma
- (2013) Brian Durie et al. JOURNAL OF MEDICAL ECONOMICS
- Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study
- (2012) Terry Golombick et al. AMERICAN JOURNAL OF HEMATOLOGY
- Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
- (2012) S. Z. Usmani et al. BLOOD
- Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form
- (2012) Angela Rago et al. CANCER
- Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma: A comparison of results in different phases of the disease
- (2012) P. Spinnato et al. EUROPEAN JOURNAL OF RADIOLOGY
- Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients
- (2012) P Falco et al. LEUKEMIA
- High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
- (2012) G Bianchi et al. LEUKEMIA
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
- (2012) T E Witzig et al. LEUKEMIA
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
- (2012) J T Larsen et al. LEUKEMIA
- Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease
- (2012) E Kastritis et al. LEUKEMIA
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma
- (2011) Shaji K. Kumar et al. CANCER
- Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study
- (2011) Giovanni D'arena et al. LEUKEMIA & LYMPHOMA
- Treatment of multiple myeloma
- (2011) S. Vincent Rajkumar Nature Reviews Clinical Oncology
- Diagnosis of Smoldering Multiple Myeloma
- (2011) S. Vincent Rajkumar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data
- (2011) D. Pulte et al. ONCOLOGIST
- Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma
- (2010) Kristen Detweiler-Short et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications
- (2010) G. Bianchi et al. BLOOD
- Incidence and follow-up of asymptomatic multiple myeloma.
- (2010) F. Wisløff et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study
- (2010) Martin Hjorth et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma
- (2010) Heinz Ludwig et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma Cell Labeling Index in the Evaluation of Smoldering (Asymptomatic) Multiple Myeloma
- (2010) Sumit Madan et al. MAYO CLINIC PROCEEDINGS
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
- (2008) B. Barlogie et al. BLOOD
- A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
- (2008) Pellegrino Musto et al. CANCER
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
- (2007) A. Dispenzieri et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now